Quick Guide: Choosing the Right DVT Test for Autoinjectors
Aligning Device Functional Testing with FDA Design Control Requirements
Developing an autoinjector requires more than confirming that the device works. Under U.S. Food and Drug Administration (FDA) Design Control requirements, manufacturers must demonstrate that device performance and function meet defined specifications and user needs.Device Verification Testing (DVT) is the stage where engineering intent becomes measurable evidence. Selecting the right tests ensures that an autoinjector’s mechanical function, dose delivery, and reliability meet regulatory expectations.
This guide outlines how to structure an effective DVT strategy and how specialist test partners can support delivery.
Why DVT Matters for Autoinjectors
Autoinjectors combine precision mechanical systems with drug delivery performance. Small deviations in force, timing, or motion can directly impact dose delivery or usability.
During design verification, testing must demonstrate that the device performs as intended across expected use conditions.
Typical objectives include:
- Confirming device functionality across the full design input range
- Demonstrating consistent dose delivery performance
- Identifying mechanical failure modes early
- Generating traceable data for regulatory submissions
A structured DVT program reduces development risk and helps avoid costly redesign later in the lifecycle.
Functional vs Performance Testing
A key step in DVT planning is distinguishing between how the device works and how well it delivers the product.
Functional TestingFunctional testing verifies that device mechanisms operate as intended. Typical examples:
These tests confirm correct physical operation of the device. |
Performance TestingPerformance testing evaluates how effectively the device delivers the drug product. Typical examples:
These tests demonstrate that delivery performance meets design specifications. |
Key Considerations When Selecting DVT Tests
1. Design Inputs and Critical Parameters
Testing should directly verify the most critical mechanical and delivery characteristics defined in the design inputs.
2. Worst-Case Conditions
DVT programs should challenge the device under realistic and extreme conditions, such as:
- Temperature extremes (see ISO 11608-1)
- Environmental exposure (vibration/free-fall per ISO 11608-1 and simulated shipping per ASTM D4169)
- Component and manufacturing tolerances
- Maximum/minimum fill volumes
- Air bubble or stopper position effects
3. Usability Considerations
Mechanical characteristics that influence user interaction should be verified, including:
- Activation force
- Injection time
- Audible and visual feedback
4. Regulatory Traceability
Each test must clearly map to a defined design input to support regulatory submissions and audit readiness.
Stability and Timepoint Strategy in DVT
Autoinjector DVT programs often include timepoint (aging) studies aligned with principles from International Council for Harmonisation (e.g. ICH Q1A(R2)).
However, these are applied using a risk-based, device-specific approach, not a fixed template.
Typical ICH-Based Timepoints
Long-term (real-time)
- 0, 3, 6, 9, 12, 18, 24 months
Accelerated
- 0, 3, 6 months
In practice, autoinjector DVT often uses a justified subset, for example:
- T0
- 3M (accelerated)
- 6M (accelerated & real-time)
- 12M
- 24M (extend to end of shelf life as necessary)
Establishment of DVT stability sample sets is typically driven by key regulatory milestones such as a New Drug Application (NDA) submission. At submission, it is typically expected that 0, 3, and 6 months of accelerated stability data are available to support initial shelf-life justification. Ongoing data for later timepoints can be submitted post-approval.
What to Test at Each Timepoint
A tiered testing strategy is typically applied based on risk, criticality, and the likelihood of change over time.
| Test Category | Typical Assessments | Typical Timing |
|---|---|---|
Core Functional & Performance Testing |
|
Every timepoint |
Mechanical & Physical Integrity |
|
Full testing at T0 and the final timepoint; reduced testing at interim intervals. |
Environmental & Robustness Testing |
|
Typically performed at T0 and/or the final timepoint. |
Human Factors-Related Checks |
|
Typically verified at T0 and the final timepoint; repeated only when risk assessment justifies additional testing. |
Key Principles for Timepoint Testing
- ICH provides a framework, not a rigid requirement for devices
- Testing should be risk-based and scientifically justified
- Combine accelerated and real-time data
- Use bracketing or reduced designs
Expectation:
- Adequate trend visibility over time
- Demonstration of performance at end-of-shelf-life (worst case)
How Smithers Can Help
Working with an experienced testing partner such as Smithers helps ensure a robust and regulator-ready DVT program.
Smithers supports autoinjector DVT through:
- Custom autoinjector DVT protocol development
- Functional testing aligned to instructions for use (IFU)
- Environmental and worst-case condition testing
- Detailed verification reports for regulatory submission
Independent testing also strengthens data credibility when preparing submissions to regulators such as the FDA. Smithers has extensive experience supporting autoinjector development programmes across early design through regulatory submission.
Summary
- DVT must demonstrate that design outputs meet design inputs
- Testing should be risk-based, targeting critical parameters that impact safety, efficacy, and usability
- Worst-case conditions and real-world use scenarios must be appropriately challenged
- Timepoint (aging) studies should be strategically designed, using justified subsets rather than exhaustive testing
- Clear traceability and well-documented rationale are essential for regulatory acceptance and audit readiness